-27.7%
PDD vs MRNA
+221.0%
-248.7%
-53.5%
Performance
Returns, benchmark comparison, and relative performance.
Performance by timeframe
Returns for 3y.
| Period | Portfolio | MRNA | Excess | Alpha |
|---|---|---|---|---|
| 1D | +1.9% | -3.4% | +5.3% | +2.0% |
| 7D | -4.9% | -12.1% | +7.2% | -4.4% |
| 30D | -3.0% | -1.3% | -1.8% | -3.2% |
| 3M | -6.2% | +250.9% | -257.1% | -14.2% |
| 6M | -20.7% | +343.0% | -363.7% | -29.8% |
| YTD | -30.4% | +657.4% | -687.8% | -43.0% |
| 1Y | -41.3% | +794.9% | -836.2% | -53.2% |
| 3Y | -27.7% | +218.1% | -245.8% | -34.0% |
| All | -27.7% | +221.0% | -248.7% | -34.0% |
Cumulative growth
Daily Returns
Daily percentage return beside MRNA.
Daily Out/Under-Performance
Portfolio return minus MRNA return. Positive bars indicate outperformance.
Daily Alpha
Portfolio daily return minus β × MRNA return. Early observations use the first valid beta; later observations use the trailing beta estimated for each date.
Cumulative Out/Under-Performance
Relative wealth over 3y: compounded portfolio wealth divided by compounded MRNA wealth, less one. Both series rebase at the selected span's start.
Cumulative Alpha
Compounded beta-adjusted residual returns apply the first valid beta to early observations, then the trailing beta ending on each date.
Updating return analytics…
3y analysis · Full analysis span regression · 6 months rolling